Search Within

Hematologic Malignancies Research

Formats
  1. Journal Article (1545)
  2. Meeting Abstract (1260)
  3. Review (76)
  4. Editorial (35)
  5. Book Section (32)
  6. Research Letter (26)
  7. Conference Paper (15)
  8. Correspondence (8)
  9. Guidelines (4)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3005)
  2. GSK Faculty (2450)
  3. Department of Medicine (2318)
  4. Hematologic Malignancies, Division of (2120)
  5. Sloan Kettering Institute Faculty (2052)
  6. Molecular Pharmacology and Chemistry Program Faculty (1632)

More Groups

People
  1. Michel Sadelain (586)
  2. David Scheinberg (502)
  3. Alexander Lesokhin (381)
  4. Carl Landgren (336)
  5. Renier Brentjens (286)
  6. Gabriela Chiosis (281)

More People

Years
  1. 2025 (64)
  2. 2024 (131)
  3. 2023 (175)
  4. 2022 (126)
  5. 2021 (154)
  6. 2020 (173)

More Years

Publications
  1. Blood (660)
  2. Cancer Research (117)
  3. Journal of Clinical Oncology (112)
  4. Clinical Lymphoma, Myeloma and Leukemia (84)
  5. Biology of Blood and Marrow Transplantation (80)
  6. Molecular Therapy (68)

More Publications

Publishers
  1. American Society of Hematology (700)
  2. Nature Publishing Group (375)
  3. Elsevier Inc. (291)
  4. American Association for Cancer Research (245)
  5. American Society of Clinical Oncology (116)
  6. Cell Press (116)

More Publishers

Results (3005)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prospective identification of unrelated donors with low inhibitory donor KIR3DL1- Recipient HLA-B interaction decreases relapse and improves survival after allogeneic hematopoietic cell transplantation for myeloid neoplasia
    Meeting Abstract

    Shaffer, B. C.; Park, S.; Le Luduec, J. B.; Devlin, S. M.; Jakubowski, A. A.; Gyurkocza, B.; Papadopoulos, E. B.; Tamari, R.; Giralt, S. A.; Hsu, K. C.
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • Durable remission following "off-the-shelf" chimeric antigen receptor (CAR) T-cells in patients with relapse/refractory (R/R) B-cell malignancies
    Meeting Abstract

    Curran, K. J.; Sauter, C. S.; Kernan, N. A.; Prockop, S. E.; Boulad, F.; Perales, M.; Giralt, S. A.; Riviere, I.; Wang, X.; Boelens, J. J.; more...
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • Hematopoietic recovery following chimeric antigen receptor T cell (CAR T) therapy in hematological malignancies
    Meeting Abstract

    Jain, T.; Knezevic, A.; Pennisi, M.; Ruiz, J. D.; Devlin, S. M.; Halton, E.; Diamonte, C.; Scordo, M.; Sauter, C. S.; Mead, E.; more...
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • Potent synergy between combination of chimeric antigen receptor (CAR) therapy targeting CD19 in conjunction with dendritic cell (DC)/tumor fusion vaccine in hematological malignancies
    Meeting Abstract

    Capelletti, M.; Liegel, J.; Themeli, M.; Mutis, T.; Stroopinsky, D.; Orr, S.; Torres, D.; Morin, A.; Gunset, G.; Ghiasuddin, H.; more...
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • Comparing car T cells toxicities grading systems: Application of ASTCT grading system and implications for management
    Meeting Abstract

    Pennisi, M.; Jain, T.; Mead, E.; Santomasso, B.; Silverberg, M. L.; Batlevi, Y.; Shouval, R.; Devlin, S. M.; Batlevi, C. W.; Brentjens, R.; more...
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • Outcomes of two chemotherapy-based preparatory regimens compared to tbi-based conditioning when used with CD34(+) selected T-cell depleted alloHCT for high risk hematologic malignancies: Prospective clinical trial NCT 01119066
    Meeting Abstract

    O'Reilly, R. J.; Koehne, G.; Boulad, F.; Heller, G.; Klein, E.; Barker, J. N.; Castro-Malaspina, H.; Curran, K. J.; Hsu, K. C.; Jakubowski, A. A.; more...
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • Time to relapse and the patterns of relapse are prognostic for post-relapse survival after CD34(+)-selected allogeneic hematopoietic stem cell transplantation in multiple myeloma
    Meeting Abstract

    Gomez-Arteaga, A.; Shah, G. L.; Baser, R. E.; Ruiz, J. D.; Bryant, A.; Chung, D. J.; Dahi, P. B.; Ghosh, A.; Lahoud, O. B.; Landau, H. J.; more...
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • Engineering strategies to overcome the current roadblocks in CAR T cell therapy
    Review

    Rafiq, S.; Hackett, C. S.; Brentjens, R. J.
    Nature Reviews Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Moving from cancer burden to cancer genomics for smoldering myeloma: A review
    Review

    Maura, F.; Bolli, N.; Rustad, E. H.; Hultcrantz, M.; Munshi, N.; Landgren, O.
    JAMA Oncology (2020)

    Fulltext@MSK | Save
  • Multiple myeloma: Current advances and future directions
    Editorial

    Landgren, C. O.
    Best Practice and Research: Clinical Haematology (2020)

    Fulltext@MSK | Save